Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Stealth Targeted Radiotherapeutics
Needham, Massachusetts, United Stateslinkedin.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Stealth BioTherapeutics has demonstrated protective effects on photoreceptor loss in Phase 2 trials of elamipretide for dry AMD. Bevemipretide, a next-generation topical candidate, has shown promising preclinical results in models of dry AMD and glaucoma. Elamipretide is under review for Barth syndrome and late-stage development for primary mitochondrial myopathy. The pipeline includes additional compounds targeting rare neurological, cardiac, and muscle diseases associated with mitochondrial dysfunction.[2][3][4]
- Therapeutic areas
- Rare DiseasesOphthalmology
- Modalities
- Peptides (mitochondria-targeted)Small molecules
- Industry
- Biotech
02
Partnerships
Not specifically listed; works with patient advocacy organizations.[2] No major pharma partnerships disclosed in search results.
Beyond the preview
Go deeper on Stealth Targeted Radiotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Stealth Targeted Radiotherapeutics.